14 results about "Antineoplastic Immunotherapeutic" patented technology

The invention discloses a temperature-sensitive gel preparation containing a glutaminase inhibitor as well as a preparation method and application of the temperature-sensitive gel preparation, and belongs to the technical field of biological medicines. The temperature-sensitive gel preparation comprises outer-layer gel and inner-layer gel, the inner-layer gel is coated with the outer-layer gel, the outer-layer gel accounts for 40-75% of the total mass of the temperature-sensitive gel preparation, and the inner-layer gel accounts for 25-60% of the total mass of the temperature-sensitive gel preparation; the outer-layer gel is prepared from the following raw materials: an outer-layer gel matrix, a glutaminase inhibitor, a photosensitizer and a stabilizer; the raw materials of the inner-layer gel comprise an inner-layer gel matrix and an immune checkpoint inhibitor. According to the temperature-sensitive gel preparation, through photo-thermal control, the glutaminase inhibitor is firstly released to relieve the immunosuppression state, then the immune checkpoint inhibitor is released to kill tumors, and the glutaminase inhibitor and the immune checkpoint inhibitor act synergistically, so that efficient anti-tumor immunotherapy is achieved.

The invention relates to a bionic intelligent microneedle tumor vaccine as well as a preparation method and application thereof. According to the vaccine, coaxial electrostatic spraying is utilized to construct a drug-loaded microsphere with a core-shell structure, the drug-loaded microsphere is coated with cancer cell-derived membrane protein, and then the drug-loaded microsphere is fixed at the needle point part of a soluble microneedle in a centrifugal manner, so that local drug delivery of crossing a cuticle layer and accurately delivering the drug-loaded microsphere to a corium layer is realized. The microsphere can load demethylated drugs DAC and TAM at the same time, and realizes responsive controlled release in a tumor microenvironment. A plurality of tumor-associated antigens and apoptosis-associated injury-associated molecular patterns carried by the cancer cell membrane protein can promote the maturation of dendritic cells and activate the specific T cell mediated anti-tumor immune response. In conclusion, the microneedle vaccine system integrates multiple functions of precise delivery, controllable release, chemical kinetics treatment, epigenetic regulation, immune activation and the like, the anti-tumor immunotherapy effect can be effectively enhanced, and a new strategy is provided for tumor immunotherapy.

The invention belongs to the field of biological medicine, and particularly relates to novel application of a functional regulator of xylosyltransferase 1 (XYLT1) in preparation of drugs for resisting human immunodeficiency virus (HIV) infection and / or resisting tumor immunotherapy. In-vitro experiments prove that up-regulation of expression or activity of XYLT1 can inhibit HIV virus replication (such as reduction of p24 antigen and virus infectivity) and enhance the curative effect of a broad-spectrum neutralizing antibody (such as 3BNC117); meanwhile, the XYLT1 can mediate the degradation of PD-L1 protein, relieve the inhibition on T cells and enhance the anti-tumor killing activity of CD8T cells. The invention provides a new target spot and a combined treatment strategy for immunotherapy of viral diseases and tumors.

This invention discloses an immune cell with enhanced anti-tumor effect, its preparation method, and its application. Experiments using this invention show that... SERTAD1 CD8 gene overexpression + T cells can enhance their function in anti-tumor immunotherapy. SERTAD1 Gene overexpression can downregulate CD8 + The expression of immune checkpoint molecules on T cells upregulates the expression of mRNAs of tumor-killing cytokines. In the MC38-OVA subcutaneous tumor model, Naïve CD8 cells were extracted from OT-I mice. + T cells were infected with a virus to overexpress SERTAD1, followed by adoptive transfer to mice. The results showed that SERTAD1 overexpression enhanced CD8 expression. + T cells kill MC38-OVA cells, inhibit the growth of MC38-OVA tumor cells, and overexpress SERTAD1 CD8. + The tumor volume and weight in the T-cell adoptive group were significantly smaller than those in the control group.

The invention discloses an application of a fusobacterium specific antibacterial peptide in preparation of a medicine for improving the anti-tumor immunotherapy effect of a PD-1 antibody. It is found that the fusobacterium specific antibacterial peptide combined with the PD-1 antibody has a remarkable tumor growth inhibition effect. According to the invention, the application range of the fusobacterium specific antibacterial peptide is expanded, and the fusobacterium specific antibacterial peptide has important significance for developing a novel anti-tumor pharmaceutical composition and establishing a novel efficient immunotherapy method.

The invention discloses a nano composition based on sequential induction and degradation and application thereof, and belongs to the technical field of biological medicine. The nano composition based on sequential induction and degradation provided by the invention comprises first nano particles and second nano particles, the first nanoparticles comprise a first carrier and an STING signal pathway agonist loaded on the first carrier; the second nanoparticle comprises a second carrier, and an E3 ligase ligand and a PD-L1 protein ligand which are loaded on the second carrier; the first nanoparticle and the second nanoparticle are configured for sequential application, and the application time of the first nanoparticle is prior to the application time of the second nanoparticle. By constructing the two functional nanoparticles which are sequentially applied, immunosuppression feedback caused by treatment can be actively intercepted and eliminated, so that tumor drug resistance is effectively reversed, and the anti-tumor immunotherapy effect is remarkably improved.

The invention relates to the field of biomedicine, in particular to a multi-immune checkpoint fusion protein as well as a preparation method and application thereof. The invention discloses a functionalized fusion protein which is composed of two modularized fusion proteins: a first module protein is a targeting module and has the function of a traditional immune checkpoint inhibitor; the second module protein is a sialidase long circulation module and has the function of a sugar immune checkpoint inhibitor; the two modular proteins can be specifically bound by a spy reaction through spontaneously formed covalent bonds. And under the synergistic effect of multi-immune checkpoint inhibition, the compound has an excellent anti-tumor immunotherapy effect.

The present invention relates to the field of immunotherapy of cancer. In particular, the present invention relates to the role of specific strains of gut bacteria, Akkermansia muciniphila Akkermansia muciniphila ) ibiome016 and ibiome017 in anti-tumor immunity, and provides methods for enhancing the response rate of patients to tumor immunotherapy.

Provided herein are nucleic acids, vectors, viral particles, and nanoparticles for delivering immunogenic cell death executioners, e.g., a N-terminal domain of gasdermin D (GSDMD) and / or a N-terminal domain of Mixed Lineage Kinase Domain Like Pseudokinase (MLKL) to cancer cells. The immunogenic cell death executioners induce necroptosis and pyroptosis, respectively, and are under the control of cancer- (e.g., epithelial cell and / or mesenchymal cell) specific promoters for treating carcinomas (e.g., breast carcinomas).

This invention provides an injectable pH-responsive hydrogel nanoparticle, its preparation method, and its applications, relating to the field of bionanomedicine technology. First, nintedanib, zinc ions, and D780 are self-assembled to prepare nanoparticles (NPs). Then, the nanoparticles are cross-linked with an OP hydrogel to obtain injectable pH-responsive hydrogel nanoparticles (OP@NPs). These OP@NPs not only possess a stable structure and injectability but also achieve efficient drug delivery through a pH-triggered release mechanism. Furthermore, OP@NPs can significantly enhance anti-tumor immune responses and effectively inhibit tumor growth by activating in vivo immune cells, improving lactate metabolism, and enhancing immune cell function. They exhibit potent anti-tumor effects and inhibition of osteosarcoma lung metastasis both in vivo and in vitro. When used in combination with the PD-1 antagonist pembrolizumab, they demonstrate great potential as a sensitizer for anti-tumor immunotherapy. This invention provides innovative strategies and new insights for osteosarcoma immunotherapy.

The invention provides an artificially synthesized flora and application of the artificially synthesized flora in auxiliary cancer immunotherapy. Specifically, the artificially synthesized flora provided by the invention is combined with an immune checkpoint inhibitor, especially a PD-1 inhibitor, so that the tumor treatment effect can be enhanced, even the drug resistance of a host to the immune checkpoint inhibitor can be reversed, and finally the effect of remarkably reducing tumors is achieved; before application, the artificially synthesized flora does not need to use antibiotics to remove original intestinal flora of an application object, and after application, the artificially synthesized flora can colonize and partially proliferate in the intestinal tract and cause overall change of intestinal flora composition. The artificially synthesized flora can be used for anti-tumor immunotherapy, improves the response rate of tumor immunotherapy people, and has a potential clinical application prospect.

The invention discloses composite paclitaxel albumin nanoparticles as well as a preparation method and application thereof, paclitaxel and a non-nucleotide interferon gene stimulating factor agonist are co-loaded by human serum albumin in a simple manner to form nanoparticles which are uniform in size, proper in particle size, relatively good in dispersity and stable in physicochemical property; the added non-nucleotide interferon gene stimulating factor agonist forms a dimer in a tumor acidic microenvironment, and active targeting of the carrier is combined, so that the nanoparticles have excellent selectivity on tumor tissues; a non-nucleotide interferon gene stimulating factor agonist starts congenital immunity and is combined with adaptive immunity of paclitaxel, so that the defect of low immune responsiveness of'cold 'tumors is overcome. In-vivo and in-vitro toxicity experiments prove that the nanoparticles provided by the invention can solve the problem of strong toxic and side effects of paclitaxel and have synergistic effects on anti-tumor immunotherapy of paclitaxel at the same time, so that the effect of combined treatment is achieved.

Provided are an anti-CCR8 antibody and an anti-CCR8 / CTLA-4 bispecific antibody, and the use thereof. Further provided are a polynucleotide, recombinant vector, host cell, chimeric antigen receptor, antibody conjugate, pharmaceutical composition and kit related to the anti-CCR8 antibody and anti-CCR8 / CTLA-4 bispecific antibody, and the related use and method. The provided antibodies can specifically target and eliminate regulatory T lymphocytes with an immunosuppressive activity infiltrating tumor tissue, and can be used in anti-tumor immunotherapy.